151
|
Rao Y, Lu M, Ge F, Marsh DJ, Qian S, Wang AH, Picciotto MR, Gao XB. Regulation of synaptic efficacy in hypocretin/orexin-containing neurons by melanin concentrating hormone in the lateral hypothalamus. J Neurosci 2008; 28:9101-10. [PMID: 18784290 PMCID: PMC2562258 DOI: 10.1523/jneurosci.1766-08.2008] [Citation(s) in RCA: 112] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2008] [Revised: 08/03/2008] [Accepted: 08/05/2008] [Indexed: 01/21/2023] Open
Abstract
The lateral hypothalamus (LH) is a central hub that integrates inputs from, and sends outputs to, many other brain areas. Two groups of neurons in the LH, expressing hypocretin/orexin or melanin concentrating hormone (MCH), have been shown to participate in sleep regulation, energy homeostasis, drug addiction, motor regulation, stress response, and social behaviors. The elucidation of crosstalk between these two systems is essential to understand these behaviors and functions because there is evidence that there are reciprocal innervations between hypocretin/orexin and MCH neurons. In this study, we used MCH receptor-1 knock-out (MCHR1 KO) and wild-type (WT) mice expressing green fluorescent protein in hypocretin/orexin-containing neurons to examine the hypothesis that MCH modulates hypocretin/orexin-mediated effects on behavioral state and synaptic transmission in the LH. In MCHR1 KO mice, the efficacy of glutamatergic synapses on hypocretin/orexin neurons is potentiated and hypocretin-1-induced action potential firing is facilitated, potentially explaining an increased effect of modafinil observed in MCHR1 KO mice. In wild-type mice with intact MCHR1 signaling, MCH significantly attenuated the hypocretin-1-induced enhancement of spike frequency in hypocretin/orexin neurons. The MCH effect was dose dependent, pertussis toxin sensitive, and was abolished in MCHR1 KO mice. Consistent with this effect, MCH attenuated hypocretin-1-induced enhancement of the frequency of miniature EPSCs in hypocretin/orexin neurons. These data from MCHR1 KO and WT mice demonstrate a novel interaction between these two systems, implying that MCH may exert a unique inhibitory influence on hypocretin/orexin signaling as a way to fine-tune the output of the LH.
Collapse
Affiliation(s)
- Yan Rao
- Departments of Obstetrics/Gynecology and Reproductive Science
| | - Min Lu
- Departments of Obstetrics/Gynecology and Reproductive Science
| | - Fei Ge
- Affiliated Haikou Hospital, Xiangya School of Medicine, Central South University, Haikou Municipal Hospital, Haikou, Hainan, 570208, China
| | - Donald J. Marsh
- Department of Metabolic Disorders, Merck Research Laboratories, Rahway, New Jersey 07065, and
| | - Su Qian
- Department of Metabolic Disorders, Merck Research Laboratories, Rahway, New Jersey 07065, and
| | | | - Marina R. Picciotto
- Psychiatry, and
- Neurobiology, Yale University School of Medicine, New Haven, Connecticut 06520
| | - Xiao-Bing Gao
- Departments of Obstetrics/Gynecology and Reproductive Science
| |
Collapse
|
152
|
Abstract
The prevalence of obesity is steadily rising and has huge health and financial implications for society. Weight gain is due to an imbalance between dietary intake and energy expenditure and research has focused on trying to understand the complex pathways involved in controlling these aspects. This review highlights the key areas of research in the hypothalamic control of appetite. The hypothalamus consists of several nuclei that integrate peripheral signals, such as adiposity and caloric intake, to regulate important pathways within the CNS controlling food intake. The best characterized pathways are the orexigenic neuropeptide Y/Agouti-related protein and the anorexigenic pro-opiomelanocortin/cocaine- and amphetamine-related transcript neurons in the arcuate nucleus of the hypothalamus. These project from the arcuate nucleus to other key hypothalamic nuclei, such as the paraventricular, dorsomedial, ventromedial and lateral hypothalamic nuclei. There are also projections to and from the brainstem, cortical areas and reward pathways, all of which influence food intake. The challenge at present is to understand the complexity of these pathways and try to find ways of modulating them in order to find potential therapeutic targets.
Collapse
Affiliation(s)
- Katherine A Simpson
- a Department of Investigative Medicine, Imperial College, London W12 ONN, UK
| | - Niamh M Martin
- a Department of Investigative Medicine, Imperial College, London W12 ONN, UK
| | - Steve R Bloom
- b Department of Investigative Medicine, Imperial College, London W12 ONN, UK.
| |
Collapse
|
153
|
Miyamoto-Matsubara M, Saitoh O, Maruyama K, Aizaki Y, Saito Y. Regulation of melanin-concentrating hormone receptor 1 signaling by RGS8 with the receptor third intracellular loop. Cell Signal 2008; 20:2084-94. [PMID: 18760349 DOI: 10.1016/j.cellsig.2008.07.019] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2008] [Revised: 07/27/2008] [Accepted: 07/31/2008] [Indexed: 11/26/2022]
Abstract
Melanin-concentrating hormone (MCH) receptor 1 (MCH1R) belongs to the class A G protein-coupled receptors (GPCRs). The MCH-MCH1R system plays a central role in energy metabolism, and thus the regulation of signaling pathways activated by this receptor is of particular interest. Regulator of G protein signaling (RGS) proteins work by increasing the GTPase activity of G protein alpha subunits and attenuate cellular responses coupled with G proteins. Recent evidence has shown that RGS proteins are not simple G protein regulators but equally inhibit the signaling from various GPCRs. Here, we demonstrate that RGS8, which is highly expressed in the brain, functions as a negative modulator of MCH1R signaling. By using biochemical approaches, RGS8 was found to selectively and directly bind to the third intracellular (i3) loop of MCH1R in vitro. When expressed in HEK293T cells, RGS8 and MCH1R colocalized to the plasma membrane and RGS8 potently inhibited the calcium mobilization induced by MCH. The N-terminal 9 amino acids of RGS8 were required for the optimal capacity to downregulate the receptor signaling. Furthermore, Arg(253) and Arg(256) at the distal end of the i3 loop were found to comprise a structurally important site for the functional interaction with RGS8, since coexpression of RGS8 with R253Q/R256Q mutant receptors resulted in a loss of induction of MCH-stimulated calcium mobilization. This functional association suggests that RGS8 may represent a new therapeutic target for the development of novel pharmaceutical agents.
Collapse
Affiliation(s)
- Mayumi Miyamoto-Matsubara
- Graduate School of Integrated Arts and Sciences, Hiroshima University, Kagamiyama, Hiroshima 739-8521, Japan
| | | | | | | | | |
Collapse
|
154
|
Pissios P, Frank L, Kennedy AR, Porter DR, Marino FE, Liu FF, Pothos EN, Maratos-Flier E. Dysregulation of the mesolimbic dopamine system and reward in MCH-/- mice. Biol Psychiatry 2008; 64:184-91. [PMID: 18281019 DOI: 10.1016/j.biopsych.2007.12.011] [Citation(s) in RCA: 57] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/20/2007] [Revised: 12/17/2007] [Accepted: 12/17/2007] [Indexed: 11/25/2022]
Abstract
BACKGROUND The hypothalamic neuropeptide melanin-concentrating hormone (MCH) plays a critical role in energy homeostasis. Abundant expression of the MCH receptor is observed outside the hypothalamus, especially in the dorsal and the ventral striatum, raising the possibility that MCH modulates the function of the midbrain dopamine neurons and associated circuitry. METHODS The MCH receptor 1 (MCHR1) expression was assessed by in situ hybridization. Expression of dopamine transporter (DAT) and the dopamine D1 and D2 receptor (D1R and D2R) subtypes in the caudate-putamen (CPu) and the nucleus accumbens (Acb) was evaluated by immunoblotting. Amperometry in ex vivo slices of the Acb was used to measure evoked-dopamine release in MCH-/ - mice. Catalepsy in MCH+/+ and MCH-/- mice was assessed by the bar test after haloperidol injection. Locomotor activity was measured after acute and chronic treatment with amphetamine and after dopamine reuptake inhibitor GBR 12909 administration. RESULTS The psychostimulant amphetamine caused enhanced behavioral sensitization in MCH-/- mice. We found significantly elevated expression of the DAT in the Acb of MCH-/- mice. The DAT-mediated uptake of dopamine was also enhanced in MCH-/- mice consistent with increased expression of DAT. We also found that evoked dopamine release is significantly increased in the Acb shell of MCH-/- mice. The GBR 12909 administration increased the locomotor activity of MCH-/- mice significantly above that of MCH+/+ mice. CONCLUSIONS These results demonstrate that MCH, in addition to its known role in feeding and weight regulation, plays a critical role in regulating Acb dopamine signaling and related behavioral responses.
Collapse
Affiliation(s)
- Pavlos Pissios
- Division of Endocrinology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA.
| | | | | | | | | | | | | | | |
Collapse
|
155
|
Kokkotou E, Moss AC, Torres D, Karagiannides I, Cheifetz A, Liu S, O'Brien M, Maratos-Flier E, Pothoulakis C. Melanin-concentrating hormone as a mediator of intestinal inflammation. Proc Natl Acad Sci U S A 2008; 105:10613-8. [PMID: 18650383 PMCID: PMC2492477 DOI: 10.1073/pnas.0804536105] [Citation(s) in RCA: 47] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2007] [Indexed: 12/23/2022] Open
Abstract
Melanin-concentrating hormone (MCH) is expressed primarily in the hypothalamus and has a positive impact on feeding behavior and energy balance. Although MCH is expressed in the gastrointestinal tract, its role in this system remains elusive. We demonstrate that, compared to wild type, mice genetically deficient in MCH had substantially reduced local inflammatory responses in a mouse model of experimental colitis induced by intracolonic administration of 2,4,6 trinitrobenzene sulfonic acid (TNBS). Likewise, mice receiving treatments with an anti-MCH antibody, either prophylactically or after the establishment of colitis, developed attenuated TNBS-associated colonic inflammation and survived longer. Consistent with a potential role of MCH in intestinal pathology, we detected increased colonic expression of MCH and its receptor in patients with inflammatory bowel disease. Moreover, we found that human colonic epithelial cells express functional MCH receptors, the activation of which induces IL-8 expression. Taken together, these results clearly implicate MCH in inflammatory processes in the intestine and perhaps elsewhere.
Collapse
Affiliation(s)
- Efi Kokkotou
- *Gastrointestinal Neuropeptide Center and Center for Inflammatory Bowel Disease
| | - Alan C. Moss
- *Gastrointestinal Neuropeptide Center and Center for Inflammatory Bowel Disease
| | - Daniel Torres
- *Gastrointestinal Neuropeptide Center and Center for Inflammatory Bowel Disease
| | | | - Adam Cheifetz
- *Gastrointestinal Neuropeptide Center and Center for Inflammatory Bowel Disease
| | - Sumei Liu
- Division of Digestive Health, Department of Internal Medicine, Ohio State University, Columbus, OH 43210; and
| | - Michael O'Brien
- Mallory Institute and Department of Pathology, Boston University School of Medicine, Boston, MA 02118
| | - Eleftheria Maratos-Flier
- Division of Gastroenterology, and Division of Endocrinology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215
| | | |
Collapse
|
156
|
Yan JH, Li QY, Boutin JA, Renard MP, Ding YX, Hao XJ, Zhao WM, Wang MW. High-throughput screening of novel antagonists on melanin-concentrating hormone receptor-1. Acta Pharmacol Sin 2008; 29:752-8. [PMID: 18501123 DOI: 10.1111/j.1745-7254.2008.00800.x] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
AIM To find new antagonists on human melanin-concentrating hormone receptor-1 (MCHR-1) through high-throughput screening (HTS) of a diverse compound library. METHODS MCHR-1, [3H]SNAP7941, and FlashBlue G-protein-coupled receptor beads were used to measure the receptor-binding activities of various compounds based on scintillation proximity assay (SPA) technology. The guanosine 5'(gamma-[35S]thio) triphosphate ([35S]GTPgammaS) binding assay was subsequently applied to functionally characterize the "hits" identified by the HTS campaign. RESULTS Of the 48,240 compounds screened with the SPA method, 12 hits were confirmed to possess MCHR-1 binding activities, 8 were functionally studied subsequently with the [35S]GTPgammaS binding assay, and only 1 compound (NC127816) displayed moderate human MCHR-1 binding affinity (Ki=115.7 nmol/L) and relatively potent antagonism (KB=23.8 nmol/L). This compound shares a novel scaffold (1-ethoxy-2H-2-aza-1-phospha-naphthalene 1-oxide) with 3 other analogs in the group. CONCLUSION Considering the marked difference in molecular shape and electrostatic status between NC127816 and the structures reported elsewhere, we anticipate that its derivatives may represent a new class of potent MCHR-1 modulators.
Collapse
Affiliation(s)
- Jian-hua Yan
- The National Center for Drug Screening and the State Key Laboratory of New Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
| | | | | | | | | | | | | | | |
Collapse
|
157
|
Cavasotto CN, Orry AJW, Murgolo NJ, Czarniecki MF, Kocsi SA, Hawes BE, O'Neill KA, Hine H, Burton MS, Voigt JH, Abagyan RA, Bayne ML, Monsma FJ. Discovery of novel chemotypes to a G-protein-coupled receptor through ligand-steered homology modeling and structure-based virtual screening. J Med Chem 2008; 51:581-8. [PMID: 18198821 DOI: 10.1021/jm070759m] [Citation(s) in RCA: 127] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Melanin-concentrating hormone receptor 1 (MCH-R1) is a G-protein-coupled receptor (GPCR) and a target for the development of therapeutics for obesity. The structure-based development of MCH-R1 and other GPCR antagonists is hampered by the lack of an available experimentally determined atomic structure. A ligand-steered homology modeling approach has been developed (where information about existing ligands is used explicitly to shape and optimize the binding site) followed by docking-based virtual screening. Top scoring compounds identified virtually were tested experimentally in an MCH-R1 competitive binding assay, and six novel chemotypes as low micromolar affinity antagonist "hits" were identified. This success rate is more than a 10-fold improvement over random high-throughput screening, which supports our ligand-steered method. Clearly, the ligand-steered homology modeling method reduces the uncertainty of structure modeling for difficult targets like GPCRs.
Collapse
|
158
|
Saito Y, Nagasaki H. The melanin-concentrating hormone system and its physiological functions. Results Probl Cell Differ 2008; 46:159-179. [PMID: 18227983 DOI: 10.1007/400_2007_052] [Citation(s) in RCA: 54] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/25/2023]
Abstract
Melanin-concentrating hormone (MCH) is a neuropeptide that was originally isolated from salmon pituitary where it causes pigment aggregation. MCH is also abundantly present in mammalian neurons and expressed in the lateral hypothalamus and zona incerta, brain regions that are known to be at the center of feeding behavior. MCH binds to and activates two G protein-coupled receptors, MCH1R and MCH2R. Although MCH2R is non-functional in rodents, genetic and pharmacological studies have demonstrated that rodent MCH1R is involved in the regulation of feeding behavior and energy balance. Unexpectedly, some antagonists have provided evidence that MCH signaling participates in the regulation of other processes, such as emotion and stress. The discovery of MCH receptors has extensively promoted the progress of MCH studies and may represent an ideal example of how deorphanized receptors can open new directions toward more detailed physiological studies.
Collapse
Affiliation(s)
- Yumiko Saito
- Graduate School of Integrated Arts and Sciences, Hiroshima University, Hiroshima, Japan.
| | | |
Collapse
|
159
|
Brown SN, Chitravanshi VC, Kawabe K, Sapru HN. Microinjections of melanin concentrating hormone into the nucleus tractus solitarius of the rat elicit depressor and bradycardic responses. Neuroscience 2007; 150:796-806. [PMID: 17988799 PMCID: PMC2199196 DOI: 10.1016/j.neuroscience.2007.10.002] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2007] [Revised: 09/28/2007] [Accepted: 10/04/2007] [Indexed: 02/07/2023]
Abstract
The presence of melanin-concentrating hormone (MCH) containing processes, projecting from the lateral hypothalamus to the medial nucleus tractus solitarius (mNTS), has been reported in the rat. It was hypothesized that MCH acting within the mNTS may modulate the central regulation of cardiovascular function. This hypothesis was tested in urethane-anesthetized, artificially ventilated, adult male Wistar rats. Microinjections (100 nl) of MCH (0.25, 0.5, 0.75, and 1 mM) into the mNTS of anesthetized rats elicited decreases in mean arterial pressure (20.4+/-1.6, 50.7+/-3.3, 35.7+/-2.8 and 30.0+/-2.6 mm Hg, respectively). The decreases in heart rate in response to these concentrations of MCH were 40.0+/-8.7, 90.0+/-13.0, 48.0+/-7.3 and 48.0+/-8.0 beats/min, respectively. Maximum cardiovascular responses were elicited by a 0.5 mM concentration of MCH. Cardiovascular responses to MCH were similar in unanesthetized mid-collicular decerebrate rats. Control microinjections of normal saline (100 nl) did not elicit any cardiovascular response. Ipsilateral or bilateral vagotomy significantly attenuated MCH-induced bradycardia. Prior microinjections of PMC-3881-PI (2 mM; MCH-1 receptor antagonist) into the mNTS blocked the cardiovascular responses to microinjections of MCH. Microinjection of MCH (0.5 mM) into the mNTS decreased efferent greater splanchnic nerve activity. Direct application of MCH (0.5 mM; 4 nl) to barosensitive nucleus tractus solitarius (NTS) neurons increased their firing rate. These results indicate that: 1) MCH microinjections into the mNTS activate MCH-1 receptors and excite barosensitive NTS neurons, causing a decrease in efferent sympathetic activity and blood pressure, and 2) MCH-induced bradycardia is mediated via the activation of the vagus nerves.
Collapse
Affiliation(s)
- S N Brown
- Department of Neurological Surgery, MSB H-586, UMDNJ-New Jersey Medical School, 185 South Orange Avenue, Newark, NJ 07103, USA
| | | | | | | |
Collapse
|
160
|
Abstract
Orphan G protein-coupled receptors (GPCRs) are receptors lacking endogenous ligands. Found by molecular biological analyses, they became the roots of reverse pharmacology, in which receptors are attempted to be matched to potential transmitters. Later, when high-throughput screening technology was applied to reverse pharmacology, dozens of orphan GPCRs became deorphanized. Furthermore, novel neuropeptides were discovered. This review retraces the history of the orphan GPCRs and of the discoveries of their endogenous ligands, it also discusses the difficulties that the search for new ligands is presently encountering.
Collapse
Affiliation(s)
- S Chung
- Department of Pharmacology, University of California Irvine, Irvine, CA, USA
| | | | | |
Collapse
|
161
|
Novak CM, Levine JA. Central neural and endocrine mechanisms of non-exercise activity thermogenesis and their potential impact on obesity. J Neuroendocrinol 2007; 19:923-40. [PMID: 18001322 DOI: 10.1111/j.1365-2826.2007.01606.x] [Citation(s) in RCA: 52] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
The rise in obesity is associated with a decline in the amount of physical activity in which people engage. The energy expended through everyday non-exercise activity, called non-exercise activity thermogenesis (NEAT), has a considerable potential impact on energy balance and weight gain. Comparatively little attention has been paid to the central mechanisms of energy expenditure and how decreases in NEAT might contribute to obesity. In this review, we first examine the sensory and endocrine mechanisms through which energy availability and energy balance are detected that may influence NEAT. Second, we describe the neural pathways that integrate these signals. Lastly, we consider the effector mechanisms that modulate NEAT through the alteration of activity levels as well as through changes in the energy efficiency of movement. Systems that regulate NEAT according to energy balance may be linked to neural circuits that modulate sleep, addiction and the stress response. The neural and endocrine systems that control NEAT are potential targets for the treatment of obesity.
Collapse
Affiliation(s)
- C M Novak
- Mayo Clinic, Endocrine Research Unit, Rochester, MN, USA.
| | | |
Collapse
|
162
|
Andersen D, Storz T, Liu P, Wang X, Li L, Fan P, Chen X, Allgeier A, Burgos A, Tedrow J, Baum J, Chen Y, Crockett R, Huang L, Syed R, Larsen RD, Martinelli M. Stereoselective Synthesis of a MCHr1 Antagonist. J Org Chem 2007; 72:9648-55. [DOI: 10.1021/jo701894v] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Denise Andersen
- Chemistry Process Research and Development, Amgen Inc., Thousand Oaks, California 19320, Medicinal Chemistry, Amgen SF, South San Francisco, California 94080, Process Chemistry, Incycte Corporation, Wilmington, Delaware 19880, and Pharmaceutical Products PPG-Sipsy, Z.I. La Croix Cadeau B.P. 79, F-49242 Avrillé Cedex, France
| | - Thomas Storz
- Chemistry Process Research and Development, Amgen Inc., Thousand Oaks, California 19320, Medicinal Chemistry, Amgen SF, South San Francisco, California 94080, Process Chemistry, Incycte Corporation, Wilmington, Delaware 19880, and Pharmaceutical Products PPG-Sipsy, Z.I. La Croix Cadeau B.P. 79, F-49242 Avrillé Cedex, France
| | - Pingli Liu
- Chemistry Process Research and Development, Amgen Inc., Thousand Oaks, California 19320, Medicinal Chemistry, Amgen SF, South San Francisco, California 94080, Process Chemistry, Incycte Corporation, Wilmington, Delaware 19880, and Pharmaceutical Products PPG-Sipsy, Z.I. La Croix Cadeau B.P. 79, F-49242 Avrillé Cedex, France
| | - Xin Wang
- Chemistry Process Research and Development, Amgen Inc., Thousand Oaks, California 19320, Medicinal Chemistry, Amgen SF, South San Francisco, California 94080, Process Chemistry, Incycte Corporation, Wilmington, Delaware 19880, and Pharmaceutical Products PPG-Sipsy, Z.I. La Croix Cadeau B.P. 79, F-49242 Avrillé Cedex, France
| | - Leping Li
- Chemistry Process Research and Development, Amgen Inc., Thousand Oaks, California 19320, Medicinal Chemistry, Amgen SF, South San Francisco, California 94080, Process Chemistry, Incycte Corporation, Wilmington, Delaware 19880, and Pharmaceutical Products PPG-Sipsy, Z.I. La Croix Cadeau B.P. 79, F-49242 Avrillé Cedex, France
| | - Pingchen Fan
- Chemistry Process Research and Development, Amgen Inc., Thousand Oaks, California 19320, Medicinal Chemistry, Amgen SF, South San Francisco, California 94080, Process Chemistry, Incycte Corporation, Wilmington, Delaware 19880, and Pharmaceutical Products PPG-Sipsy, Z.I. La Croix Cadeau B.P. 79, F-49242 Avrillé Cedex, France
| | - Xiaoqi Chen
- Chemistry Process Research and Development, Amgen Inc., Thousand Oaks, California 19320, Medicinal Chemistry, Amgen SF, South San Francisco, California 94080, Process Chemistry, Incycte Corporation, Wilmington, Delaware 19880, and Pharmaceutical Products PPG-Sipsy, Z.I. La Croix Cadeau B.P. 79, F-49242 Avrillé Cedex, France
| | - Alan Allgeier
- Chemistry Process Research and Development, Amgen Inc., Thousand Oaks, California 19320, Medicinal Chemistry, Amgen SF, South San Francisco, California 94080, Process Chemistry, Incycte Corporation, Wilmington, Delaware 19880, and Pharmaceutical Products PPG-Sipsy, Z.I. La Croix Cadeau B.P. 79, F-49242 Avrillé Cedex, France
| | - Alain Burgos
- Chemistry Process Research and Development, Amgen Inc., Thousand Oaks, California 19320, Medicinal Chemistry, Amgen SF, South San Francisco, California 94080, Process Chemistry, Incycte Corporation, Wilmington, Delaware 19880, and Pharmaceutical Products PPG-Sipsy, Z.I. La Croix Cadeau B.P. 79, F-49242 Avrillé Cedex, France
| | - Jason Tedrow
- Chemistry Process Research and Development, Amgen Inc., Thousand Oaks, California 19320, Medicinal Chemistry, Amgen SF, South San Francisco, California 94080, Process Chemistry, Incycte Corporation, Wilmington, Delaware 19880, and Pharmaceutical Products PPG-Sipsy, Z.I. La Croix Cadeau B.P. 79, F-49242 Avrillé Cedex, France
| | - Jean Baum
- Chemistry Process Research and Development, Amgen Inc., Thousand Oaks, California 19320, Medicinal Chemistry, Amgen SF, South San Francisco, California 94080, Process Chemistry, Incycte Corporation, Wilmington, Delaware 19880, and Pharmaceutical Products PPG-Sipsy, Z.I. La Croix Cadeau B.P. 79, F-49242 Avrillé Cedex, France
| | - Ying Chen
- Chemistry Process Research and Development, Amgen Inc., Thousand Oaks, California 19320, Medicinal Chemistry, Amgen SF, South San Francisco, California 94080, Process Chemistry, Incycte Corporation, Wilmington, Delaware 19880, and Pharmaceutical Products PPG-Sipsy, Z.I. La Croix Cadeau B.P. 79, F-49242 Avrillé Cedex, France
| | - Rich Crockett
- Chemistry Process Research and Development, Amgen Inc., Thousand Oaks, California 19320, Medicinal Chemistry, Amgen SF, South San Francisco, California 94080, Process Chemistry, Incycte Corporation, Wilmington, Delaware 19880, and Pharmaceutical Products PPG-Sipsy, Z.I. La Croix Cadeau B.P. 79, F-49242 Avrillé Cedex, France
| | - Liang Huang
- Chemistry Process Research and Development, Amgen Inc., Thousand Oaks, California 19320, Medicinal Chemistry, Amgen SF, South San Francisco, California 94080, Process Chemistry, Incycte Corporation, Wilmington, Delaware 19880, and Pharmaceutical Products PPG-Sipsy, Z.I. La Croix Cadeau B.P. 79, F-49242 Avrillé Cedex, France
| | - Rashid Syed
- Chemistry Process Research and Development, Amgen Inc., Thousand Oaks, California 19320, Medicinal Chemistry, Amgen SF, South San Francisco, California 94080, Process Chemistry, Incycte Corporation, Wilmington, Delaware 19880, and Pharmaceutical Products PPG-Sipsy, Z.I. La Croix Cadeau B.P. 79, F-49242 Avrillé Cedex, France
| | - Robert D. Larsen
- Chemistry Process Research and Development, Amgen Inc., Thousand Oaks, California 19320, Medicinal Chemistry, Amgen SF, South San Francisco, California 94080, Process Chemistry, Incycte Corporation, Wilmington, Delaware 19880, and Pharmaceutical Products PPG-Sipsy, Z.I. La Croix Cadeau B.P. 79, F-49242 Avrillé Cedex, France
| | - Mike Martinelli
- Chemistry Process Research and Development, Amgen Inc., Thousand Oaks, California 19320, Medicinal Chemistry, Amgen SF, South San Francisco, California 94080, Process Chemistry, Incycte Corporation, Wilmington, Delaware 19880, and Pharmaceutical Products PPG-Sipsy, Z.I. La Croix Cadeau B.P. 79, F-49242 Avrillé Cedex, France
| |
Collapse
|
163
|
Harrold JA, Halford JCG. Orphan G-protein-coupled receptors : strategies for identifying ligands and potential for use in eating disorders. Drugs R D 2007; 8:287-99. [PMID: 17767394 DOI: 10.2165/00126839-200708050-00003] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023] Open
Abstract
G-protein-coupled receptors (GPCRs) are key regulators of intercellular interactions, participating in almost every physiological response. They exert their effects by being activated by a variety of endogenous ligands. Traditionally, these ligands were identified first, providing tools to characterise the receptors. However, since the late 1980s, homology screening approaches have allowed the GPCRs to be found first, and in turn used as orphan targets to identify their ligands. Over the last decade this method has led to the identification of 12 novel neuropeptide families. Interestingly, four of these deorphanised GPCR systems, melanin-concentrating hormone, ghrelin, orexin and neuropeptide B/neuropeptide W, have been found to play a role in the control of energy balance. This article reviews the role of these GPCR systems in the control of food intake and energy expenditure, and discusses their potential use in therapies directed at eating disorders. As obesity has reached epidemic proportions across the developed world, pharmacotherapy has focused on this condition. However, difficulties in weight control also characterise disorders of binge eating such as bulimia and binge-eating disorder. Consequently, hypophagic treatments may be of potential benefit in normal, overweight or obese individuals displaying aberrant (out of control) eating behaviour.
Collapse
Affiliation(s)
- Joanne A Harrold
- Kissileff Laboratory for the Study of Human Ingestive Behaviour, School of Psychology, University of Liverpool, Liverpool, UK.
| | | |
Collapse
|
164
|
Méndez-Andino JL, Wos JA. MCH-R1 antagonists: what is keeping most research programs away from the clinic? Drug Discov Today 2007; 12:972-9. [DOI: 10.1016/j.drudis.2007.08.010] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2007] [Revised: 08/08/2007] [Accepted: 08/21/2007] [Indexed: 10/22/2022]
|
165
|
Rokosz LL. Discovery and development of melanin-concentrating hormone receptor 1 antagonists for the treatment of obesity. Expert Opin Drug Discov 2007; 2:1301-27. [DOI: 10.1517/17460441.2.10.1301] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
166
|
Su J, Tang H, McKittrick BA, Gu H, Guo T, Qian G, Burnett DA, Clader JW, Greenlee WJ, Hawes BE, O'neill K, Spar B, Weig B, Kowalski T, Sorota S. Synthesis of novel bicyclo[4.1.0]heptane and bicyclo[3.1.0]hexane derivatives as melanin-concentrating hormone receptor R1 antagonists. Bioorg Med Chem Lett 2007; 17:4845-50. [PMID: 17604169 DOI: 10.1016/j.bmcl.2007.06.048] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2007] [Revised: 06/11/2007] [Accepted: 06/13/2007] [Indexed: 10/23/2022]
Abstract
To address the hERG liability of MCHR1 antagonists such as 1 and 2, new analogs such as 4 and 5 that incorporated a polar heteroaryl group were designed and synthesized. Biological evaluation confirmed that these new analogs retained MCH R1 activity with greatly attenuated hERG liabilities as indicated in the Rb efflux assay.
Collapse
Affiliation(s)
- Jing Su
- Department of Chemical Research, Schering-Plough Research Institute K15 2545, Kenilworth, NJ 07033, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
167
|
Jiang Y, Chen CA, Lu K, Daniewska I, De Leon J, Kong R, Forray C, Li B, Hegde LG, Wolinsky TD, Craig DA, Wetzel JM, Andersen K, Marzabadi MR. Synthesis and SAR Investigations for Novel Melanin-Concentrating Hormone 1 Receptor (MCH1) Antagonists Part 1. The Discovery of Arylacetamides as Viable Replacements for the Dihydropyrimidinone Moiety of an HTS Hit. J Med Chem 2007; 50:3870-82. [PMID: 17668921 DOI: 10.1021/jm060381c] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Melanin-concentrating hormone (MCH) is involved in the regulation of feeding, water balance, energy metabolism, general arousal and attention state, memory, cognitive functions, and psychiatric disorders. Herein, two new chemical series exemplified by N-[5-(1-{3-[2,2-bis-(4-fluoro-phenyl)-acetylamino]-propyl}-piperidin-4-yl)-2,4-difluoro-phenyl]-isobutyramide (SNAP 102739, 5m) and N-[3-(1-{3-[(S)-2-(4-fluoro-phenyl)-propionylamino]-propyl}-piperidin-4-yl)-4-methylphenyl]-isobutyramide ((S)-6b) are reported. These compounds were designed to improve the pharmacokinetic properties of the high-throughput screening lead compound 1 (SNAP 7941). The MCH1 receptor antagonists 5m and (S)-6b show reasonable pharmacokinetic profiles (rat bioavailability = 48 and 81%, respectively). Compounds 5m and (S)-6b demonstrated the inhibition of a centrally administered MCH-evoked drinking effect, and compound 5m exhibited oral in vivo efficacy in the rat social interaction model of anxiety, with a minimum effective dose = 0.3 mg/kg.
Collapse
Affiliation(s)
- Yu Jiang
- Departments of Chemistry, Cellular Science, and Target Discovery and Assessment, Lundbeck Research USA, Inc., 215 College Road, Paramus, NJ 07652-1413, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
168
|
Chen CA, Jiang Y, Lu K, Daniewska I, Mazza CG, Negron L, Forray C, Parola T, Li B, Hegde LG, Wolinsky TD, Craig DA, Kong R, Wetzel JM, Andersen K, Marzabadi MR. Synthesis and SAR Investigations for Novel Melanin-Concentrating Hormone 1 Receptor (MCH1) Antagonists Part 2: A Hybrid Strategy Combining Key Fragments of HTS Hits. J Med Chem 2007; 50:3883-90. [PMID: 17668922 DOI: 10.1021/jm060383x] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
A novel series of melanin-concentrating hormone (MCH1) receptor antagonists based on combining key fragments from the high-throughput screening (HTS) hits compound 2 (SNAP 7941) and compound 5 (chlorohaloperidol) are described. The resultant analogs, exemplified by compounds 11a-11h, 15a-15h, and 16a-16g, were evaluated in in vitro and in vivo assays for their potential in treatment of mood disorders. From further SAR investigations, N-(3-{1-[4-(3,4-difluorophenoxy)benzyl]-4-piperidinyl}-4-methylphenyl)-2-methylpropanamide (16g, SNAP 94847) was identified to be a high affinity and selective ligand for the MCH1 receptor. Compound 16g also shows good oral bioavailability (59%) and exhibits a brain/plasma ratio of 2.3 in rats. Compound 16g showed in vivo inhibition of a centrally induced MCH-induced drinking effect and exhibited a dose-dependent anxiolytic effect in the rat social interaction model.
Collapse
Affiliation(s)
- Chien-An Chen
- Departments of Chemistry, Cellular Science and Target Discovery and Assessment, Lundbeck Research USA, Inc., 215 College Road, Paramus, NJ 07652-1413, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
169
|
Trinko R, Sears RM, Guarnieri DJ, DiLeone RJ. Neural mechanisms underlying obesity and drug addiction. Physiol Behav 2007; 91:499-505. [PMID: 17292426 DOI: 10.1016/j.physbeh.2007.01.001] [Citation(s) in RCA: 52] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2006] [Revised: 01/08/2007] [Accepted: 01/08/2007] [Indexed: 11/29/2022]
Abstract
Increasing rates of obesity have alarmed health officials and prompted much public dialogue. While the factors leading to obesity are numerous, an inability to control intake of freely available food is central to the problem. In order to understand this, we need to better define the mechanisms by which the brain regulates food intake, and why it is often difficult to control consumption. From this point of view, it seems valuable to consider the commonalities between food intake and drug abuse. While research in the two fields has historically emphasized different neural substrates, recent data have increased interest in better defining elements that may underlie both drug addiction and obesity. Here we discuss some of these shared elements with an emphasis on emerging areas of research that better define common mechanisms leading to overconsumption.
Collapse
Affiliation(s)
- Richard Trinko
- Department of Psychiatry, Yale University School of Medicine, New Haven, CT 06519, USA
| | | | | | | |
Collapse
|
170
|
Su J, McKittrick BA, Tang H, Burnett DA, Clader JW, Greenlee WJ, Hawes BE, O'Neill K, Spar B, Weig B, Kowalski T, Sorota S, Li C, Liu T. SAR study of bicyclo[4.1.0]heptanes as melanin-concentrating hormone receptor R1 antagonists: Taming hERG. Bioorg Med Chem 2007; 15:5369-85. [PMID: 17572094 DOI: 10.1016/j.bmc.2007.05.068] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2007] [Revised: 05/23/2007] [Accepted: 05/29/2007] [Indexed: 11/18/2022]
Abstract
To improve the ex vivo potency of MCH inhibitor 1a and to address its hERG liability, a structure-activity study was carried out, focusing on three regions of the lead structure. Introduction of new side chains with basic nitrogen improved in vitro and ex vivo bindings. Many potent compounds with K(i)<10nM were discovered (compounds 6a-j) and several compounds (14-17) had excellent ex vivo binding at 6h and 24h. Attenuating the basicity of nitrogen on the side chain, and in particular, introduction of a polar group such as aminomethyl on the distal phenyl ring significantly lowered the hERG activity. Further replacement of the distal phenyl group with heteroaryl groups in the cyclohexene series provided compounds such as 28l with excellent ex vivo activity with much reduced hERG liability.
Collapse
Affiliation(s)
- Jing Su
- Department of Chemical Research, Schering-Plough Research Institute K15 2545, 2015 Galloping Hill Road, Kenilworth, NJ 07033, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
171
|
Sandig H, McDonald J, Gilmour J, Arno M, Lee TH, Cousins DJ. Human Th2 cells selectively express the orexigenic peptide, pro-melanin-concentrating hormone. Proc Natl Acad Sci U S A 2007; 104:12440-4. [PMID: 17640905 PMCID: PMC1941487 DOI: 10.1073/pnas.0705457104] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2007] [Indexed: 12/14/2022] Open
Abstract
Th1 and Th2 cells represent the two main functional subsets of CD4(+) T helper cell, and are defined by their cytokine expression. Human Th1 cells express IFNgamma, whilst Th2 cells express IL-4, IL-5, and IL-13. Th1 and Th2 cells have distinct immunological functions, and can drive different immunopathologies. Here, we show that in vitro-differentiated human Th2 cells highly selectively express the gene for pro-melanin-concentrating hormone (PMCH), using real-time RT-PCR, enzyme immunoassay, and Western blot analysis. PMCH encodes the prohormone, promelanin-concentrating hormone (PMCH), which is proteolytically processed to produce several peptides, including the orexigenic hormone melanin-concentrating hormone (MCH). PMCH expression by Th2 cells was activation responsive and increased throughout the 28-day differentiation in parallel with the expression of the Th2 cytokine genes. MCH immunoreactivity was detected in the differentiated Th2 but not Th1 cell culture supernatants after activation, and contained the entire PMCH protein, in addition to several smaller peptides. Human Th1 and Th2 cells were isolated by their expression of IFNgamma and CRTH2, respectively, and the ex vivo Th2 cells expressed PMCH upon activation, in contrast to the Th1 cells. Because Th2 cells are central to the pathogenesis of allergic diseases including asthma, expression of PMCH by activated Th2 cells in vivo may directly link allergic inflammation to energy homeostasis and may contribute to the association between asthma and obesity.
Collapse
Affiliation(s)
- Hilary Sandig
- *Medical Research Council–Asthma U.K. Centre in Allergic Mechanisms of Asthma and
| | - Joanne McDonald
- *Medical Research Council–Asthma U.K. Centre in Allergic Mechanisms of Asthma and
| | - Jane Gilmour
- *Medical Research Council–Asthma U.K. Centre in Allergic Mechanisms of Asthma and
| | - Matthew Arno
- Genomics Centre, King's College London, London SE1 9RT, United Kingdom
| | - Tak H. Lee
- *Medical Research Council–Asthma U.K. Centre in Allergic Mechanisms of Asthma and
| | - David J. Cousins
- *Medical Research Council–Asthma U.K. Centre in Allergic Mechanisms of Asthma and
| |
Collapse
|
172
|
Saito Y. [Role of MCH-MCH receptor system in feeding and depression]. Nihon Yakurigaku Zasshi 2007; 130:34-8. [PMID: 17634678 DOI: 10.1254/fpj.130.34] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/16/2023]
|
173
|
Luthin DR. Anti-obesity effects of small molecule melanin-concentrating hormone receptor 1 (MCHR1) antagonists. Life Sci 2007; 81:423-40. [PMID: 17655875 DOI: 10.1016/j.lfs.2007.05.029] [Citation(s) in RCA: 59] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2007] [Revised: 05/09/2007] [Accepted: 05/18/2007] [Indexed: 10/23/2022]
Abstract
Over the past ten years, tremendous advances in our understanding of the role of the hypothalamic neurohormone, melanin-concentrating hormone (MCH), and its involvement in the regulation of food intake and body weight have been achieved. The MCHR1 receptor has been actively targeted as a much-needed, novel treatment for obesity, a disease of epidemic proportion in the United States. Numerous companies have joined the competition to be the first to produce a small molecule antagonist targeting MCHR1 receptors in the race for therapeutics for this disease. This review details the rising need for new treatments for obesity; the rationale and target validation of MCHR1 receptor antagonists as potential treatments for this disease; and the current status of the numerous small molecule MCHR1 antagonists in development by different companies. MCHR1 antagonists might find an additional usage in the treatment of anxiety and depression disorders. The rationale and current status of this effort by several companies is also reviewed.
Collapse
Affiliation(s)
- David R Luthin
- Samford University, McWhorter School of Pharmacy, 800 Lakeshore Drive, Birmingham, AL 35229, USA.
| |
Collapse
|
174
|
Abstract
Obesity is a major public health problem associated with morbidity and mortality and continues to increase worldwide. This review focuses on the regions of the brain that are important in appetite regulation and the circulating factors implicated in the control of food intake. The hypothalamus is critical in the regulation of food intake containing neural circuits, which produce a number of peptides that influence food intake. The arcuate nucleus of the hypothalamus produces both orexigenic peptides (agouti-related protein and neuropeptide Y) and anorectic peptides (alpha-melanocyte-stimulating hormone and cocaine- and amphetamine-related transcript). The lateral hypothalamus produces the orexigenic peptides (melanin-concentrating hormone and orexins). Other hypothalamic factors recently implicated in appetite regulation include the endocannabinoids, brain-derived neurotrophic factor, nesfatin-1, AMP-activated protein kinase, mammalian target of rapamycin protein, and protein tyrosine phosphatase. Circulating factors that affect food intake mediate their effects by signaling to the hypothalamus and/or brainstem. A number of circulating factors are produced by peripheral organs, for example, leptin by adipose tissue, insulin and pancreatic polypeptide by the pancreas, gut hormones (e.g., ghrelin, obestatin, glucagon-like peptide-1, oxyntomodulin, peptide YY), and triiodothyronine by the thyroid gland. Circulating carbohydrates, lipids, and amino acids also affect appetite regulation. Knowledge regarding appetite regulation has vastly expanded in recent years providing targets for antiobesity drug design.
Collapse
Affiliation(s)
- Waljit S Dhillo
- Department of Metabolic Medicine, Hammersmith Hospital, Imperial College London, London, United Kingdom.
| |
Collapse
|
175
|
Coumans B, Grisar T, Nahon JL, Lakaye B. Effect of ppMCH derived peptides on PBMC proliferation and cytokine expression. ACTA ACUST UNITED AC 2007; 143:104-8. [PMID: 17537530 DOI: 10.1016/j.regpep.2007.04.001] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2006] [Revised: 03/05/2007] [Accepted: 04/11/2007] [Indexed: 11/26/2022]
Abstract
The mRNA encoding prepro-Melanin concentrating hormone (ppMCH) is mainly expressed in the central nervous system but has also been detected at lower amount in many peripheral tissues including spleen and thymus. At the peptide level however, several forms of the precursor can be detected in these tissues and are sometimes expressed at similar levels compared to brain. In the present work, we have studied the in vitro action of a wide range of concentration (1 nM to 1 microM) of the different peptides encoded by ppMCH i.e. neuropeptide glycine-glutamic acid (NGE), neuropeptide glutamic acid-isoleucine (NEI), Melanin concentrating hormone (MCH) and the dipeptide NEI-MCH on peripheral blood mononuclear cells (PBMC) proliferation and cytokine production following anti-CD3 stimulation. Among them only MCH decreased PBMC proliferation with a maximal effect of 35% at 100 nM. Moreover as demonstrated by using ELISA, MCH significantly decreases IL-2 production by 25% but not IL-4, INF-gamma or TNF-alpha expression. Interestingly, exogenous IL-2 decreases significantly MCH-mediated inhibition, suggesting that it is an important downstream mediator of MCH action. Finally, we showed that after 7 to 9 days of incubation, MCH also inhibits proliferation of non-stimulated PBMC. Altogether, these data demonstrate that fully mature MCH modulates proliferation of anti-CD3 stimulated PBMC partially through regulation of IL-2 production.
Collapse
Affiliation(s)
- Bernard Coumans
- Center for Cellular and Molecular Neurobiology, University of Liège, Liège, Belgium
| | | | | | | |
Collapse
|
176
|
Design and synthesis of novel hydantoin-containing melanin-concentrating hormone receptor antagonists. Bioorg Med Chem Lett 2007; 17:3754-9. [PMID: 17448659 DOI: 10.1016/j.bmcl.2007.04.012] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2007] [Revised: 03/31/2007] [Accepted: 04/05/2007] [Indexed: 11/16/2022]
Abstract
We report here new chemical series acting as antagonists of melanin-concentrating hormone receptor 1 (MCHR-1). Synthesis and structure-activity relationships are described leading to the identification of compounds with optimized in vitro pharmacological and in vitro ADME profiles. In vivo activity has been demonstrated in animal models of food intake and depression.
Collapse
|
177
|
Takahashi A, Kosugi T, Kobayashi Y, Yamanome T, Schiöth HB, Kawauchi H. The melanin-concentrating hormone receptor 2 (MCH-R2) mediates the effect of MCH to control body color for background adaptation in the barfin flounder. Gen Comp Endocrinol 2007; 151:210-9. [PMID: 17324419 DOI: 10.1016/j.ygcen.2007.01.011] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/13/2006] [Revised: 01/12/2007] [Accepted: 01/19/2007] [Indexed: 10/23/2022]
Abstract
Melanin-concentrating hormone (MCH) is a neuropeptide generated in neurons originating in the hypothalamus, from which axons project to the entire brain and neurohypophysis in fish. MCH has both central and peripheral roles such as food intake and body color change. Here we cloned two MCH receptors (MCH-R) from the barfin flounder, Verasper moseri, Pleuronectiformes. The phylogenetic analysis shows that these are orthologues to the mammalian MCH-R1 and MCH-R2 showing 49 and 30% amino acid sequence identity to the corresponding human receptors while they have 31% amino acid sequence identify between them. Essential amino acid residues for ligand binding, signal transduction and receptor conformation, which have been shown in mammalian MCH-R, are well conserved in the flounder MCH-Rs. MCH-R1 has one intron in the extracellular N-terminal region and MCH-R2 has one intron in the DRY motif, which is a homologous position to one of the five introns of human MCH-R2. Orthologues of MCH-R1 and MCH-R2 may have appeared by gene duplication of the ancestry of MCH-Rs having at least two introns, and then MCH-R1 and MCH-R2 inherited different introns in flounder strains. We also determined their tissue distribution and functional role in rearing condition. Reverse transcription PCR revealed that the expression of MCH-R1 is confined to the brain of the barfin flounder, while transcripts of MCH-R2 were detected in the brain, pituitary, eyeball, gill, atrium, ventricle, head kidney, body kidney, spleen, intestine, inclinator, skeletal muscle testis, ovary, eyed-side skin, and non-eyed-side skin. The expression of MCH-R2 in eyed-side skin was higher in fish reared in a black tank (121 days) than in a white tank while the expression levels of MCH in the brain were significantly greater in the group reared with the white background suggesting down-regulation of this receptor gene with increased levels of MCH. The results suggest that the MCH-R2 mediates the effect of MCH to control body color for background adaptation in the eyed-side skin of the barfin flounder.
Collapse
Affiliation(s)
- Akiyoshi Takahashi
- School of Fisheries Sciences, Kitasato University, Ofunato, Iwate 022-0101, Japan.
| | | | | | | | | | | |
Collapse
|
178
|
David DJ, Klemenhagen KC, Holick KA, Saxe MD, Mendez I, Santarelli L, Craig DA, Zhong H, Swanson CJ, Hegde LG, Ping XI, Dong D, Marzabadi MR, Gerald CP, Hen R. Efficacy of the MCHR1 antagonist N-[3-(1-{[4-(3,4-difluorophenoxy)phenyl]methyl}(4-piperidyl))-4-methylphenyl]-2-methylpropanamide (SNAP 94847) in mouse models of anxiety and depression following acute and chronic administration is independent of hippocampal neurogenesis. J Pharmacol Exp Ther 2007; 321:237-48. [PMID: 17237257 DOI: 10.1124/jpet.106.109678] [Citation(s) in RCA: 99] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
Melanin-concentrating hormone (MCH) is a hypothalamic neuropeptide that plays a role in the modulation of food intake and mood. In rodents, the actions of MCH are mediated via the MCHR1 receptor. The goal of this study was to investigate the effects of acute (1 h) and chronic (28 days) p.o. dosing of a novel MCHR1 antagonist, N-[3-(1-{[4-(3,4-difluorophenoxy)-phenyl]methyl}(4-piperidyl))-4-methylphenyl]-2-methylpropanamide (SNAP 94847), in three mouse models predictive of antidepressant/anxiolytic-like activity: novelty suppressed feeding (NSF) in 129S6/SvEvTac mice and light/dark paradigm (L/D) and forced swim test (FST) in BALB/cJ mice. A significant increase in the time spent in the light compartment of the L/D box was observed in response to acute and chronic treatment with SNAP 94847. An anxiolytic/antidepressant-like effect was found in the NSF test after acute and chronic treatment, whereas no effect was observed in the FST. Because neurogenesis in the dentate gyrus has been shown to be a requirement for the effects of antidepressants in the NSF test, we investigated whether neurogenesis was required for the effect of SNAP 94847. We showed that chronic treatment with SNAP 94847 stimulated proliferation of progenitors in the dentate gyrus. The efficacy of SNAP 94847 in the NSF test, however, was unaltered in mice in which neurogenesis was suppressed by X-irradiation. These results indicate that SNAP 94847 has a unique anxiolytic-like profile after both acute and chronic administration and that its mechanism of action is distinct from that of selective serotonin reuptake inhibitors and tricyclic antidepressants.
Collapse
Affiliation(s)
- D J David
- Center for Neurobiology and Behavior, Columbia University, New York, New York, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
179
|
Guo T, Gu H, Hobbs DW, Busler DE, Rokosz LL. Discovery of tetralin ureas as potent melanin concentrating hormone 1 receptor antagonists. Bioorg Med Chem Lett 2007; 17:1718-21. [PMID: 17251014 DOI: 10.1016/j.bmcl.2006.12.080] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2006] [Revised: 12/14/2006] [Accepted: 12/18/2006] [Indexed: 11/23/2022]
Abstract
Melanin concentrating hormone (MCH) plays an important role in the regulation of food intake and energy balance in mammals. MCH-1 receptor (MCH1R) deficient mice are lean and resistant to diet-induced obesity. As such, MCH1R antagonists are believed to have potential as possible treatments for obesity. The discovery of a novel class of tetralin ureas as potent MCH1R antagonists is described herein.
Collapse
Affiliation(s)
- Tao Guo
- Pharmacopeia Drug Discovery Inc., PO Box 5350, Princeton, NJ 08543-5350, USA.
| | | | | | | | | |
Collapse
|
180
|
Wigglesworth MJ, Wolfe LA, Wise A. Orphan seven transmembrane receptor screening. ERNST SCHERING FOUNDATION SYMPOSIUM PROCEEDINGS 2007:105-43. [PMID: 17703580 DOI: 10.1007/2789_2006_006] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
Drug discovery has successfully exploited the superfamily of seven transmembrane receptors (7TMR), with over 35% of clinically marketed drugs targeting them. However, it is clear that there remains an undefined potential within this protein family for successful drugs of the future. The human genome sequencing project identified approximately 720 genes that belong to the 7TMR superfamily. Around half of these genes encode sensory receptors, while the other half are potential drug targets. Natural ligands have been identified for approximately 215 of these, leaving 155 receptors classified as orphan 7TMRs having no known ligand. Deorphanisation of these receptors by identification of natural ligands has been the traditional method enabling target validation by use of these ligands as tools to define biological relevance and disease association. Such ligands have been paired with their cognate receptor experimentally by screening of small molecule and peptide ligands, reverse pharmacology and the use of bioinformatics to predict candidate ligands. In this manuscript, we review the methodologies developed for the identification of ligands at orphan 7TMRs and exemplify these with case studies.
Collapse
Affiliation(s)
- M J Wigglesworth
- Screening and Compound Profiling, GlaxoSmithKline, New Frontiers Science Park, Third Avenue, Harlow, CM19 5AW Essex, UK.
| | | | | |
Collapse
|
181
|
Abstract
There is compelling genetic and pharmacologic evidence to indicate that melanin-concentrating hormone receptor-1 (MCHR1) signaling is involved in the regulation of food intake and energy expenditure. The medical need for novel therapies to treat obesity and related metabolic disorders has led to a great deal of interest by pharmaceutical companies in the discovery of MCHR1 antagonists. Recent publications describing preclinical studies have demonstrated that small-molecule MCHR1 antagonists decrease food intake, bodyweight, and adiposity in rodent models of obesity. Results from ongoing early-stage clinical trials with MCHR1 antagonists are eagerly awaited, as is the movement of other MCHR1 antagonists into the clinic.
Collapse
Affiliation(s)
- Timothy J Kowalski
- Department of CV/Metabolic Diseases, Schering-Plough Research Institute, Kenilworth, New Jersey 07033, USA.
| | | |
Collapse
|
182
|
Cooke D, Bloom S. The obesity pipeline: current strategies in the development of anti-obesity drugs. Nat Rev Drug Discov 2006; 5:919-31. [PMID: 17080028 DOI: 10.1038/nrd2136] [Citation(s) in RCA: 134] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
This review provides a summary of currently available pharmaceutical therapies for the treatment of obesity, along with an overview of the pipeline of products currently in development, and the key mechanisms on which the major development candidates are based. In particular, the recent increase in understanding of the role of gut peptides in energy homeostasis is highlighted as a promising source of potential future obesity therapies.
Collapse
Affiliation(s)
- Dunstan Cooke
- Thiakis Limited, Imperial BioIncubator, Bessemer Building (RSM), Prince Consort Road, London SW7 2BP, UK
| | | |
Collapse
|
183
|
Tavares FX, Al-Barazanji KA, Bigham EC, Bishop MJ, Britt CS, Carlton DL, Feldman PL, Goetz AS, Grizzle MK, Guo YC, Handlon AL, Hertzog DL, Ignar DM, Lang DG, Ott RJ, Peat AJ, Zhou HQ. Potent, Selective, and Orally Efficacious Antagonists of Melanin-Concentrating Hormone Receptor 1. J Med Chem 2006; 49:7095-107. [PMID: 17125262 DOI: 10.1021/jm060572f] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
The high expression of MCH in the hypothalamus with the lean hypophagic phenotype coupled with increased resting metabolic rate and resistance to high fat diet-induced obesity of MCH KO mice has spurred considerable efforts to develop small molecule MCHR1 antagonists. Starting from a lead thienopyrimidinone series, structure-activity studies at the 3- and 6-positions of the thienopyrimidinone core afforded potent and selective MCHR1 antagonists with representative examples having suitable pharmacokinetic properties. Based on structure-activity relationships, a structural model for MCHR1 was constructed to explain the binding mode of these antagonists. In general, a good correlation was observed between pKas and activity in the right-hand side of the template, with Asp123 playing an important role in the enhancement of binding affinity. A representative example when evaluated chronically in diet-induced obese mice resulted in good weight loss effects. These antagonists provide a viable lead series in the discovery of new therapies for the treatment of obesity.
Collapse
Affiliation(s)
- Francis X Tavares
- Department of Medicinal Chemistry, GlaxoSmithKline, Research Triangle Park, North Carolina 27709, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
184
|
Schwarz DA, Allen MM, Petroski RE, Pomeroy JE, Heise CE, Mistry MS, Selkirk JV, Nottebaum LM, Grey J, Zhang M, Goodfellow VS, Maki RA. Manipulation of small-molecule inhibitory kinetics modulates MCH-R1 function. Mol Cell Endocrinol 2006; 259:1-9. [PMID: 16987592 DOI: 10.1016/j.mce.2006.07.003] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/21/2006] [Revised: 05/25/2006] [Accepted: 07/24/2006] [Indexed: 11/29/2022]
Abstract
The capacity of novel benzopyridazinone-based antagonists to inhibit MCH-R1 function, relative to their affinity for the receptor, has been investigated. Three compounds that differ by the addition of either a chlorine atom, or trifluoromethyl group, have nearly identical receptor affinities; however their abilities to inhibit receptor elicited signaling events, measured as a function of time, are dramatically altered. Both the chlorinated and trifluoromethyl modified compounds have a very slow on-rate to maximal functional inhibition relative to the unmodified base compound. A similar impact on inhibitory capacity can be achieved by modifying the side-chain composition at position 2.53 of the receptor; replacement of the native phenylalanine with alanine significantly reduces the amount of time required by the chlorinated compound to attain maximal functional inhibition. The primary attribute responsible for this alteration in inhibitory capacity appears to be the overall bulk of the amino acid at this position-substitution of the similarly sized amino acids leucine and tyrosine results in phenotypes that are indistinguishable from the wild type receptor. Finally, the impact of these differential inhibitory kinetics has been examined in cultured rat neurons by measuring the ability of the compounds to reverse MCH mediated inhibition of calcium currents. As observed using the cell expression models, the chlorinated compound has a diminished capacity to interfere with receptor function. Collectively, these data suggest that differential inhibitory on rates between a small-molecule antagonist and its target receptor can impact the ability of the compound to modify the biological response(s) elicited by the receptor.
Collapse
Affiliation(s)
- David A Schwarz
- Neurocrine Biosciences, Inc., Department of Molecular Biology, 12790 El Camino Real, San Diego, CA 92130, USA.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
185
|
Abstract
Melanin-concentrating hormone (MCH) was originally discovered in fish, in which it causes aggregation or concentration of melanin granules in melanophores, thus regulating body color. MCH is a cyclic neuropeptide synthesized as a preprohormone in the hypothalamus of all vertebrates. Mammalian MCH plays an important role as a neurotransmitter or neuromodulator in regulating food intake and energy homeostasis. MCH signaling system may involve in regulating food intake also in fish. This neuropeptide binds to G-protein-coupled seven transmembrane receptor[s] to mediate its functions. This article reviews MCH and MCH receptor signaling systems in body color change and food intake in fish.
Collapse
Affiliation(s)
- Hiroshi Kawauchi
- Laboratory of Molecular Endocrinology, School of Fisheries Sciences, Kitasato University, Sanriku, Ofunato, Iwate 022-0101, Japan.
| |
Collapse
|
186
|
Ma V, Bannon AW, Baumgartner J, Hale C, Hsieh F, Hulme C, Rorrer K, Salon J, van Staden C, Tempest P. Solid-phase synthesis and structure–activity relationships of novel biarylethers as melanin-concentrating hormone receptor-1 antagonists. Bioorg Med Chem Lett 2006; 16:5066-72. [PMID: 16887348 DOI: 10.1016/j.bmcl.2006.07.040] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2006] [Revised: 07/11/2006] [Accepted: 07/12/2006] [Indexed: 11/29/2022]
Abstract
Melanin-concentrating hormone (MCH) is a cyclic 19 amino acid orexigenic neuropeptide. The action of MCH on feeding is thought to involve the activation of its respective G protein-coupled receptor MCH-R1. Consequently, antagonists that block MCH regulated MCH-R1 activity may provide a viable approach to the treatment of diet-induced obesity. This communication reports the discovery of a novel MCH-R1 receptor antagonist, the biarylether 7, identified through high throughput screening. The solid-phase synthesis and structure-activity relationship of related analogs is described.
Collapse
Affiliation(s)
- Vu Ma
- Chemistry Research and Discovery, Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
187
|
Pissios P, Bradley RL, Maratos-Flier E. Expanding the scales: The multiple roles of MCH in regulating energy balance and other biological functions. Endocr Rev 2006; 27:606-20. [PMID: 16788162 DOI: 10.1210/er.2006-0021] [Citation(s) in RCA: 159] [Impact Index Per Article: 8.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Melanin-concentrating hormone (MCH) is a cyclic peptide originally identified as a 17-amino-acid circulating hormone in teleost fish, where it is secreted by the pituitary in response to stress and environmental stimuli. In fish, MCH lightens skin color by stimulating aggregation of melanosomes, pigment-containing granules in melanophores, cells of neuroectodermal origin found in fish scales. Although the peptide structure between fish and mammals is highly conserved, in mammals, MCH has no demonstrable effects on pigmentation; instead, based on a series of pharmacological and genetic experiments, MCH has emerged as a critical hypothalamic regulator of energy homeostasis, having effects on both feeding behavior and energy expenditure.
Collapse
Affiliation(s)
- Pavlos Pissios
- Division of Endocrinology, Department of Medicine, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, Massachusetts 02215, USA
| | | | | |
Collapse
|
188
|
Handlon AL, Zhou H. Melanin-concentrating hormone-1 receptor antagonists for the treatment of obesity. J Med Chem 2006; 49:4017-22. [PMID: 16821761 DOI: 10.1021/jm058239j] [Citation(s) in RCA: 37] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Anthony L Handlon
- Metabolic and Viral Center of Excellence for Drug Discovery, GlaxoSmithKline, P.O. Box 13398, Research Triangle Park, North Carolina 27709-3398, USA.
| | | |
Collapse
|
189
|
Witty DR, Bateson J, Hervieu GJ, Al-Barazanji K, Jeffrey P, Hamprecht D, Haynes A, Johnson CN, Muir AI, O'Hanlon PJ, Stemp G, Stevens AJ, Thewlis K, Winborn KY. Discovery of potent and stable conformationally constrained analogues of the MCH R1 antagonist SB-568849. Bioorg Med Chem Lett 2006; 16:4872-8. [PMID: 16839763 DOI: 10.1016/j.bmcl.2006.06.061] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2006] [Revised: 06/15/2006] [Accepted: 06/17/2006] [Indexed: 11/19/2022]
Abstract
A strategy of systematically targeting more rigid analogues of the known MCH R1 receptor antagonist, SB-568849, serendipitously uncovered a binding mode accessible to N-aryl-phthalimide ligands. Optimisation to improve the stability of this compound class led to the discovery of novel N-aryl-quinazolinones, benzotriazinones and thienopyrimidinones as selective ligands with good affinity for human melanin-concentrating hormone receptor 1.
Collapse
Affiliation(s)
- David R Witty
- GlaxoSmithKline, New Frontiers Science Park, Third Avenue, Harlow, Essex CM19 5AW, UK.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
190
|
Witty DR, Bateson JH, Hervieu GJ, Jeffrey P, Johnson CN, Muir AI, O'Hanlon PJ, Stemp G, Stevens AJ, Thewlis KM, Wilson S, Winborn KY. SAR of biphenyl carboxamide ligands of the human melanin-concentrating hormone receptor 1 (MCH R1): Discovery of antagonist SB-568849. Bioorg Med Chem Lett 2006; 16:4865-71. [PMID: 16839761 DOI: 10.1016/j.bmcl.2006.06.056] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2006] [Revised: 06/14/2006] [Accepted: 06/15/2006] [Indexed: 11/29/2022]
Abstract
We report here the discovery of a class of MCH R1 ligands based on a biphenyl carboxamide template. A docked-in model is presented indicating key interactions in the putative binding site of the receptor. Parallel high throughput synthetic techniques were utilised to allow rapid exploration of the structure-activity relationship around this template, leading to compound SB-568849 which possessed good receptor affinity and selectivity. This compound proved to be an antagonist with stability in vivo, an acceptable brain-blood ratio and oral bioavailability.
Collapse
Affiliation(s)
- David R Witty
- GlaxoSmithKline, New Frontiers Science Park, Third Avenue, Harlow, Essex CM19 5AW, UK.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
191
|
Francke F, Ward RJ, Jenkins L, Kellett E, Richter D, Milligan G, Bächner D. Interaction of neurochondrin with the melanin-concentrating hormone receptor 1 interferes with G protein-coupled signal transduction but not agonist-mediated internalization. J Biol Chem 2006; 281:32496-507. [PMID: 16945926 DOI: 10.1074/jbc.m602889200] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Screening of a human brain cDNA library using the C-terminal tail of the melanin-concentrating hormone receptor 1 (MCHR1) as bait in a yeast two-hybrid assay resulted in the identification of the neurite-outgrowth related factor, neurochondrin. This interaction was verified in overlay, pulldown, and co-immunoprecipitation assays. Deletion mapping confined the binding to the C terminus of neurochondrin and to the proximal C terminus of MCHR1, a region known to be involved in G protein binding and signal transduction. This region of the MCHR1 is also able to interact with the actin- and intermediate filament-binding protein, periplakin. Interactions of MCHR1 with neurochondrin and periplakin were competitive, indicating that these two proteins bind to overlapping regions of MCHR1. Although neurochondrin did not interfere with melanin-concentrating hormone-mediated internalization of the receptor, it did inhibit G protein-coupled signal transduction via both Galpha(i/o) and Galpha(q/11) family G proteins as measured by each of melanin-concentrating hormone-induced G protein-activated inwardly rectifying K(+) channel activity of voltage-clamped amphibian oocytes, by calcium mobilization in transfected mammalian cells, and by reduction in the capacity of melanin-concentrating hormone to promote binding of [(35)S]guanosine 5'-3-O-(thio)triphosphate to both Galpha(o1) and Galpha(11). Immunohistochemistry revealed co-expression of neurochondrin and MCHR1 within the rodent brain, suggesting that neurochondrin may be involved in the regulation of MCHR1 signaling and play a role in modulating melanin-concentrating hormone-mediated functions in vivo.
Collapse
Affiliation(s)
- Felix Francke
- Institute for Cell Biochemistry and Clinical Neurobiology, University Hospital Hamburg-Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany
| | | | | | | | | | | | | |
Collapse
|
192
|
Chung S, Civelli O. Orphan neuropeptides. Novel neuropeptides modulating sleep or feeding. Neuropeptides 2006; 40:233-43. [PMID: 16814380 DOI: 10.1016/j.npep.2006.04.002] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/07/2006] [Revised: 04/12/2006] [Accepted: 04/14/2006] [Indexed: 10/24/2022]
Abstract
Neuropeptides form the largest family of modulators of synaptic transmission. Until 1995 some 60 different neuropeptides had been found. With the recognition that all neuropeptides act by binding to G protein coupled receptors (GPCRs), a new approach relying on the use of orphan GPCRs as targets was designed to identify novel neuropeptides. Thirteen new neuropeptide families have since been discovered. In this review we will describe the orphan GPCR-based approach that led to these discoveries and present its impact on two specific physiological responses, feeding and sleep. In particular, we will discuss the modulatory roles of the hypocretins/orexins and of neuropeptide S in sleep and awakening and those of ghrelin and melanin concentrating hormone in food intake.
Collapse
Affiliation(s)
- Shinjae Chung
- Department of Pharmacology, University of California Irvine, Irvine, CA 92697, USA
| | | |
Collapse
|
193
|
|
194
|
Biaryl piperidine melanin-concentrating hormone-1 receptor antagonists for obesity. Drug Discov Today 2006. [DOI: 10.1016/j.drudis.2006.06.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
195
|
Nahon JL. The melanocortins and melanin-concentrating hormone in the central regulation of feeding behavior and energy homeostasis. C R Biol 2006; 329:623-38; discussion 653-5. [PMID: 16860280 DOI: 10.1016/j.crvi.2006.03.021] [Citation(s) in RCA: 83] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2006] [Accepted: 03/08/2006] [Indexed: 11/16/2022]
Abstract
A number of different neuropeptides exert powerful concerted controls on feeding behavior and energy balance, most of them being produced in hypothalamic neuronal networks under stimulation by anabolic and catabolic peripheral hormones such as ghrelin and leptin, respectively. These peptide-expressing neurons interconnect extensively to integrate the multiple opposing signals that mediate changes in energy expenditure. In the present review I have summarized our current knowledge about two key peptidic systems involved in regulating appetite and energy homeostasis, the melanocortin system (alpha-MSH, agouti and Agouti-related peptides, MC receptors and mahogany protein) and the melanin-concentrating hormone system (proMCH-derived peptides and MCH receptors) that contribute to satiety and feeding-initiation, respectively, with concurrent effects on energy expenditure. I have focused particularly on recent data concerning transgenic mice and the ongoing development of MC/MCH receptor antagonists/agonists that may represent promising drugs to treat human eating disorders on both sides of the energy balance (anorexia, obesity).
Collapse
Affiliation(s)
- Jean-Louis Nahon
- Institut de pharmacologie moléculaire et cellulaire, UMR 6097, Centre national de la recherche scientifique (CNRS), 660, route des Lucioles, Sophia-Antipolis, 06560 Valbonne, France.
| |
Collapse
|
196
|
Severinsen JE, Als TD, Binderup H, Kruse TA, Wang AG, Vang M, Muir WJ, Blackwood DHR, Mors O, Børglum AD. Association analyses suggest GPR24 as a shared susceptibility gene for bipolar affective disorder and schizophrenia. Am J Med Genet B Neuropsychiatr Genet 2006; 141B:524-33. [PMID: 16741940 DOI: 10.1002/ajmg.b.30335] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
Linkage analyses suggest that chromosome 22q12-13 may harbor a shared susceptibility locus for bipolar affective disorder (BPD) and schizophrenia (SZ). In a study of a sample from the Faeroe Islands we have previously reported association between both disorders and microsatellite markers in a 3.6 cM segment on 22q13. The present study investigated three candidate genes located in this segment: GPR24, ADSL, and ST13. Nine SNPs located in these genes and one microsatellite marker (D22S279) were applied in an association analysis of two samples: an extension of the previously analyzed Faeroese sample comprising 28 distantly related cases (17 BPD, 11 SZ subjects) and 44 controls, and a Scottish sample including 162 patients with BPD, 103 with SZ, and 200 controls. In both samples significant associations were observed in both disorders with predominantly GPR24 SNPs and haplotypes. In the Faeroese sample overall P-values of 0.0009, 0.0054, and 0.0023 were found for haplotypes in BPD, SZ, and combined cases, respectively, and in the Scottish sample overall P-values of 0.0003, 0.0005, and 0.016 were observed for similar groupings. Specific haplotypes showed associations with lowest P-values of 7 x 10(-5) and 0.0006 in the combined group of cases from the Faeroe Islands and Scotland, respectively. The G protein-coupled receptor 24 encoded by GPR24 binds melanin-concentrating hormone (MCH) and has been implicated with feeding behavior, energy metabolism, and regulation of stress and mood. To our knowledge this is the first study reporting association between GPR24 and BPD and SZ, suggesting that GPR24 variants may confer susceptibility to both disorders.
Collapse
Affiliation(s)
- J E Severinsen
- Institute of Human Genetics, University of Aarhus, Aarhus, Denmark
| | | | | | | | | | | | | | | | | | | |
Collapse
|
197
|
Wu WL, Burnett DA, Caplen MA, Domalski MS, Bennett C, Greenlee WJ, Hawes BE, O'Neill K, Weig B, Weston D, Spar B, Kowalski T. Design and synthesis of orally efficacious benzimidazoles as melanin-concentrating hormone receptor 1 antagonists. Bioorg Med Chem Lett 2006; 16:3674-8. [PMID: 16690315 DOI: 10.1016/j.bmcl.2006.04.062] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2006] [Revised: 04/21/2006] [Accepted: 04/21/2006] [Indexed: 11/16/2022]
Abstract
Biaryl urea lead compound 1 was discovered earlier in our MCH antagonist program. Novel benzimidazole analogues with increased chemical stability, devoid of the potential carcinogenic liability associated with a biarylamine moiety, were synthesized and evaluated to be potent MCH R1 antagonists. Two compounds in this series have demonstrated in vivo efficacy in a rodent obesity model.
Collapse
Affiliation(s)
- Wen-Lian Wu
- Schering Plough Research Institute, 2015 Galloping Hill Road, MS 2800, Kenilworth, NJ 07033-0539, USA.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
198
|
Wu WL, Burnett DA, Spring R, Qiang L, Sasikumar TK, Domalski MS, Greenlee WJ, O'Neill K, Hawes BE. Synthesis and structure–activity relationships of piperidine-based melanin-concentrating hormone receptor 1 antagonists. Bioorg Med Chem Lett 2006; 16:3668-73. [PMID: 16690312 DOI: 10.1016/j.bmcl.2006.04.061] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2006] [Revised: 04/21/2006] [Accepted: 04/21/2006] [Indexed: 10/24/2022]
Abstract
Isosteric replacement of the urea group of lead compound 1 led to novel substituted piperidine phenylamide analogues. SAR on the electron-induced effects of various linkers as well as substituents on the phenyl rings and the piperidine nitrogen has been investigated. Many single-digit nanomolar MCH R1 antagonists have been identified from this series.
Collapse
Affiliation(s)
- Wen-Lian Wu
- Schering Plough Research Institute, 2015 Galloping Hill Road, MS 2800, Kenilworth, NJ 07033-0539, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
199
|
Logan DW, Burn SF, Jackson IJ. Regulation of pigmentation in zebrafish melanophores. PIGMENT CELL RESEARCH 2006; 19:206-13. [PMID: 16704454 DOI: 10.1111/j.1600-0749.2006.00307.x] [Citation(s) in RCA: 132] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
In comparison with the molecular genetics of melanogenesis in mammals, the regulation of pigmentation in poikilothermic vertebrates is poorly understood. Mammals undergo morphological colour change under hormonal control, but strikingly, many lower vertebrates display a rapid physiological colour change in response to the same hormones. The recent provision of extensive genome sequencing data from teleost zebrafish, Danio rerio, provides the opportunity to define the genes and proteins mediating this physiological pigment response and characterise their function biologically. Here, we illustrate the background adaptation process in adults and larvae and describe a novel assay to visualize and directly quantify the rate of zebrafish melanophore pigment translocation in unprecedented detail. We demonstrate the resolution of this assay system; quantifying the zebrafish melanophore response to melanin-concentrating and melanocyte-stimulating hormones. Furthermore, we investigate the intracellular signalling downstream of hormone stimulation and the biomechanical processes involved in zebrafish pigment translocation, confirming the importance of cyclic adenosine monophosphate (cAMP) as a mediator of pigment translocation and finding intact microtubules are essential for both melanin dispersion and aggregation in zebrafish, but that microfilament disruption affects aggregation only. In conclusion, we propose these data establish the zebrafish as an experimental model for studying both physiological colour change and the molecular basis of pigment translocation.
Collapse
Affiliation(s)
- Darren W Logan
- MRC Human Genetics Unit, Western General Hospital, Edinburgh, UK
| | | | | |
Collapse
|
200
|
Smith DG, Davis RJ, Rorick-Kehn L, Morin M, Witkin JM, McKinzie DL, Nomikos GG, Gehlert DR. Melanin-concentrating hormone-1 receptor modulates neuroendocrine, behavioral, and corticolimbic neurochemical stress responses in mice. Neuropsychopharmacology 2006; 31:1135-45. [PMID: 16205780 DOI: 10.1038/sj.npp.1300913] [Citation(s) in RCA: 76] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Repeated exposure to stressful conditions is linked to the etiology of affective disorders. The melanin-concentrating hormone-1 receptor (MCHR1) may be a novel mechanism that is involved in the modulation of stress responses and affective states. The role of MCHR1 in neuroendocrine, behavioral, and neurochemical stress, and anxiety-related responses was examined by monitoring the effects of melanin-concentrating hormone (MCH) and the selective MCHR1 antagonist, GW3430, in inbred C57Bl/6NTac and MCHR1-knockout (KO) and wild-type (WT) mice. Intracerebroventricular injection of MCH increased plasma corticosterone, and produced anxiety-related responses in the elevated plus maze. The selective MCHR1 antagonist, GW3430, blocked the neuroendocrine and behavioral effects of MCH and produced anxiolytic-like effects by itself in animal models of anxiety. Moreover, KO mice had an anxiolytic-like phenotype in behavioral models of anxiety, and GW3430 had anxiolytic-like effects in WT, but not KO mice. Lastly, stressor-evoked acetylcholine release within the prefrontal cortex of inbred and WT mice, but not KO mice, was blocked by GW3430. We show that MCH elicits anxiety-like responses and that the effects of a selective MCHR1 antagonist and the phenotype of KO mice are consistent with anxiolytic-like action. Distinct behavioral, physiological, and neurochemical stress, and anxiety-related responses were selectively modulated by the MCHR1, and these actions may involve corticolimbic regulation of stress responsivity and anxiety.
Collapse
MESH Headings
- Acetylcholine/metabolism
- Adrenocorticotropic Hormone/blood
- Alprazolam/pharmacology
- Animals
- Anti-Anxiety Agents/pharmacology
- Behavior, Animal/drug effects
- Behavior, Animal/physiology
- Body Temperature/drug effects
- Brain Chemistry/drug effects
- Brain Chemistry/physiology
- Corticosterone/blood
- Dose-Response Relationship, Drug
- Hypothalamic Hormones/administration & dosage
- Male
- Maze Learning/drug effects
- Maze Learning/physiology
- Melanins/administration & dosage
- Mice
- Mice, Inbred C57BL
- Mice, Knockout
- Neurosecretory Systems/drug effects
- Neurosecretory Systems/metabolism
- Pituitary Hormones/administration & dosage
- Random Allocation
- Receptors, Somatostatin/antagonists & inhibitors
- Receptors, Somatostatin/deficiency
- Receptors, Somatostatin/physiology
- Stress, Physiological/metabolism
- Stress, Physiological/physiopathology
- Stress, Physiological/psychology
Collapse
Affiliation(s)
- Daniel G Smith
- Neuroscience Discovery Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA.
| | | | | | | | | | | | | | | |
Collapse
|